质母细胞瘤的个性化慢性治疗:整合昼夜分析和PK-PD建模,以优化temozolomide的时间

Nina Nelson1, Oliver Zimmer1, Angela Relógio2,3

  • 1Institute for Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany.

NPJ precision oncology
|December 12, 2025
PubMed
概括

个性化慢性疗法可以改善质母细胞瘤治疗. 调整temozolomide (TMZ) 与身体的昼夜时钟,以遗传特征和数学模型为指导,可以提高药物的疗效和患者的治疗结果.